Teladoc Health (NYSE:TDOC) Price Target Raised to $7.00 at Citigroup

Key Points

• Citigroup raised its price target on Teladoc from $6.00 to $7.00 while maintaining a "neutral" rating, implying roughly a 3.95% upside from the prior close.
• Analyst coverage is mixed with a MarketBeat consensus of "Hold", an average target of $7.53, and a breakdown of 5 Buys, 12 Holds and 1 Sell.
• Teladoc reported Q1 EPS of ($0.36) (missed by $0.01) and revenue of $613.85M (slightly above estimates), and issued FY2026 guidance of -1.05 to -0.75 EPS (analysts forecast -0.89).

Teladoc Health (NYSE:TDOC - Get Free Report) had its price target raised by equities researchers at Citigroup from $6.00 to $7.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "neutral" rating on the health services provider's stock. Citigroup's price objective points to a potential upside of 3.95% from the company's previous close.

A number of other research firms have also recently commented on TDOC. Deutsche Bank Aktiengesellschaft raised Teladoc Health from a "hold" rating to a "buy" rating and set a $11.00 price target on the stock in a report on Tuesday, March 10th. Leerink Partners lowered their target price on Teladoc Health from $8.50 to $5.50 and set a "market perform" rating for the company in a research report on Thursday, February 26th. Barclays cut their target price on shares of Teladoc Health from $8.50 to $7.00 and set an "equal weight" rating for the company in a report on Thursday, March 26th. Piper Sandler restated an "overweight" rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a research report on Thursday, February 26th. Finally, TD Cowen decreased their price target on shares of Teladoc Health from $8.00 to $6.00 and set a "hold" rating on the stock in a research note on Thursday, February 26th. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Teladoc Health has a consensus rating of "Hold" and a consensus target price of $7.53.

Teladoc Health Stock Performance

TDOC traded up $0.10 during midday trading on Tuesday, reaching $6.73. The company had a trading volume of 2,187,717 shares, compared to its average volume of 5,977,283. The business has a 50-day moving average of $5.40 and a two-hundred day moving average of $6.43. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.77. The company has a market cap of $1.22 billion, a P/E ratio of -6.94 and a beta of 2.08.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.01). The company had revenue of $613.85 million for the quarter, compared to analysts' expectations of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm's quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050--0.750 EPS and its Q2 2026 guidance at -0.300--0.200 EPS. As a group, equities research analysts predict that Teladoc Health will post -0.89 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 27,731 shares of the business's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the transaction, the chief executive officer owned 364,784 shares of the company's stock, valued at approximately $2,002,664.16. The trade was a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.70% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Jupiter Asset Management Ltd. grew its holdings in Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider's stock valued at $27,021,000 after purchasing an additional 2,880,008 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider's stock worth $53,260,000 after purchasing an additional 1,325,106 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Teladoc Health during the fourth quarter valued at approximately $9,156,000. Monaco Asset Management SAM boosted its position in shares of Teladoc Health by 159.2% during the fourth quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider's stock valued at $13,699,000 after buying an additional 1,201,947 shares during the period. Finally, Allianz Asset Management GmbH grew its stake in shares of Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider's stock valued at $12,518,000 after buying an additional 1,059,458 shares during the last quarter. Institutional investors own 76.82% of the company's stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.